ClinicalTrials.gg
RecruitingNCT07166601TITERUpdated Nov 2, 2026

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

A Phase 1 interventional study of M0324 and M0324 in Advanced Solid Tumor, sponsored by EMD Serono Research & Development Institute, Inc.. Recruiting at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany — 1 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck KGaA, Darmstadt, Germany.

Planned enrollment
20th of 34
77 · median 143
Started
2025
with 1 other
Phase 1
12 of 35
1 open now
Registered
35th of 35
by date

Among the 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany, this one is the 20th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 in phase 1, and was the 35th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany is open now, in 3 countries.

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary signs of efficacy, pharmacokinetics (PK), and pharmacodynamics (PD). Three different treatments with M0324 will be studied, M0324 as a monotherapy(Part 1), M0324 in combination with pembrolizumab (Part 2), and in combination with mFOLFIRINOX (a chemotherapy treatment)(Part 3).

03

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Bispecific CD40 agonistic antibody
  • Mucin-1 (MUC-1)
  • pembrolizumab
  • mFOLFIRINOX
  • pancreatic ductal adenocarcinoma (PDAC)
  • non-small cell lung cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1- M0324 Monotherapy:

  • Participants with certain advanced/ solid tumor types known to overexpress MUC-1 and who are intolerant or to standard therapy or for which no standard therapy is judged appropriate by the Investigator

Part 2- M0324 Combination with Pembrolizumab:

  • Participants with certain advanced/metastatic tumor types known to overexpress MUC-1 and the participants in the combination treatment involving M0324 and pembrolizumab must be intolerant or refractory to standard therapy and no other further standard therapy should be judged appropriate by the Investigator. In addition, the participants must have had prior treatment with (s) (ICIs) and must have experienced documented disease progression on or after ICIs.

Part 3- M0324 Combination with mFOLFIRINOX:

  • Participants with previously untreated metastatic pancreatic ductal adenocarcinoma, who are judged by Investigator as eligible for treatment with mFOLFIRINOX. Participants with prior Whipple surgery and/or chemotherapy are not permitted
  • Other protocol defined inclusion criteria could apply.

Exclusion criteria

Exclusion Criteria:

  • Has a history of chronic diarrhea greater than or equal to (>=) Grade 2, inflammatory disease of the colon or rectum, or unresolved partial or complete intestinal obstruction
  • Participant has a history of within 3 years before the date of enrollment
  • Uncontrolled or poorly controlled arterial hypertension, uncontrolled cardiac arrhythmia, unstable angina, myocardial infarction, congestive heart failure [ (NYHA) >= II] or a coronary revascularization procedure within 180 days of study entry
  • of less than 3 months
  • Other protocol defined exclusion criteria could apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
77 participants (estimated)

Study arms

  • Experimental
    Part 1: M0324 Monotherapy

    Biological: M0324

  • Experimental
    Part 2: M0324 + Pembrolizumab

    Biological: M0324 · Biological: Pembrolizumab

  • Experimental
    Part 3: M0324 + mFOLFIRINOX

    Biological: M0324 · Drug: mFOLFIRINOX

Interventions

  • BiologicalM0324

    M0324 will be tested at increasing doses as monotherapy to determine dose-toxicity relationship and MTD (if reached) in order to support selection of recommended dose(s) for expansion (RDE).

  • BiologicalM0324

    M0324 will be further investigated in part 2 and part 3 of the study as combination regimen, in order to determine dose-toxicity relationship in combination and MTD (if reached) in order to support selection of RDE(s) in combination.

  • BiologicalPembrolizumab

    Pembrolizumab will be administered intravenously as per standard of care.

  • DrugmFOLFIRINOX

    mFOLFIRINOX will be administered intravenously as per standard of care.

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)

    Time frame: Day 1 up to Day 21

  2. Part 1, 2 and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Month 40

  3. Part 3: Number of Participants With Dose Limiting Toxicities (DLTs)

    Time frame: Day 1 up to Day 35

Secondary outcomes

  1. Parts 1 and 2: Pharmacokinetic (PK) Plasma Concentrations of M0324

    Time frame: From Day 1 up to approximately 40 months

  2. Parts 3: Pharmacokinetic (PK) Plasma Concentrations of M0324

    Time frame: From Day 1 up to approximately 40 months

  3. Percent Change from Baseline in Pharmacodynamic Markers

    Pharmacodynamic and circulating biomarkers (e.g. cytokines) will be measured in blood.

    Time frame: From Day 1 up to approximately 40 months

  4. Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigator

    Time frame: Time from first study treatment until progressive disease or death up to approximately 40 months

  5. Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Time frame: Time from first study treatment until first documentation of progressive disease (PD) or death, assessed approximately up to 40 months

  6. Duration of Response (DoR) According to RECIST v1.1 as Assessed by Investigator

    Time frame: Time from first documentation of OR until progressive disease (PD) or death, assessed approximately up to 40 months

  7. Part 3: Overall Survival (OS)

    Time frame: Time from first study treatment until death, assessed approximately up to 40 months

  8. Number of Participants With Positive Anti-Drug Antibody (ADA) of M0324

    Time frame: Up to Month 40

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2029, 40 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 40 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 10, 2025
StartActual
Oct 10, 2025
Primary completionEst.
Feb 23, 2029
CompletionEst.
Feb 23, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and criteria formatting
2 updates, last Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Minor edits only
    + 1 other change: criteria formatting
  2. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07166601
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Oct 10, 2025
Primary completion
Feb 23, 2029 (estimated)
Completion
Feb 23, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

US Medical Information
Contact
eMediUSA@emdserono.com
888-275-7376
Communication Center
Contact
service@emdgroup.com
+49 6151 72 5200
Medical Responsible
study director · EMD Serono Research & Development Institute, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion